Research summary
Nomyx Technology Labs is a Delaware software company of nine people that sells tokenization software to asset managers. On 23 September 2026 it filed a Form 1-A to sell up to $20 million of Revenue Participation Bonds, Series 2026, at $10 each under Regulation A Tier 2. Each bond is an unsecured general obligation paying 8% a year, quarterly, from a pool of 10% of platform revenues or from general funds, due seven years after its own issue date, with one warrant to buy a common share at $12. The bonds are sold as Bond Tokens on a chain the circular names only as Trusted Smart Chain; T7X Equity, the transfer agent, would mint every token into its own omnibus wallet, and its off-chain file is the only record of ownership. Anyone may buy: accredited investors without limit, others up to 10% of income or net worth. The minimum is $2,000. There is no redemption right; principal comes back at year seven unless Nomyx redeems after year three at a premium. The program is rejected. The offering statement is not qualified, so nothing can be sold; the issuer made $133,285 in 2025 and lost $1.93 million, and its auditor doubts it can continue; the transfer agent’s affiliate is also the issuer’s bridge lender and would take a 10% bond bonus for investing; and the token cannot leave the transfer agent’s wallet. The reopen condition is qualification by the SEC with a published contract, after which the file is read again.
Observable review triggers
- The SEC qualifies the Form 1-A for CIK 2065495 and Nomyx publishes the Bond Token contract address and chain; the file is then read with the control-surface reader
- Nomyx files a Form 1-K showing bonds sold, pool deposits made, and every quarterly priority return paid on time
- T7X whitelists investor wallets and enables transfers out of the omnibus wallet, or an ATS lists the bonds
- The T7X Assets bridge notes are repaid or converted and the transfer agent’s affiliate no longer holds Nomyx debt
Facts on file
- Research assessment
- Adverse
- Client selection
- Not considered
- Exposure
- tokenized RWA
- Chains examined
- Reviewed
- Next review